Myoinositol trends in different types of brain lesions

Myoinositol (Myo) is a not yet well known metabolite detected using short echo time proton magnetic resonance spectroscopy (HMRS). We examined the role of Myo in 26 patients with new diagnosis of brain lesions including tumors, inflammatory and infectious processes. Histological confirmation of the diagnosis was obtained during gross total surgical resection or stereotactic biopsy of the lesions. The highest ratios of Myo/Cr were found in the hemangiopericytoma and meningioma followed by cortical dysplasia, low grade gliomas, gliobastomas, lymphomas, demyelinating lesions and toxoplasmosis. There was no Myo detected in the cases of metastasis and abscess. Increased Myo levels correlated with low grade gliomas suggesting its potential use in the differentiation of glial tumor. Myo demonstrated a unique pattern in hemangiopericytoma.